ASX:TLXBiotechs
Telix Pharmaceuticals (ASX:TLX) Gains Portugal Approval for Illuccix in Prostate Cancer Detection
Telix Pharmaceuticals (ASX:TLX) recently gained marketing authorization for its prostate cancer imaging agent, Illuccix®, in Portugal. This development enhances diagnostic options in a country where prostate cancer is prevalently diagnosed. Last week, the company's share price rose by 3%, a move that aligns with its recent regulatory success. Although the broader market remained steady over the same period, Telix's approval could provide additional support to its stock performance. The growth...